Search results for " FIBROSIS"

showing 10 items of 490 documents

WNT2b activates epithelial-mesenchymal transition through FZD4: relevance in penetrating Crohns disease.

2020

Abstract Background and Aims Epithelial-mesenchymal transition [EMT] has been related to fibrosis and fistula formation, common complications associated with Crohn´s disease [CD]. The WNT signalling pathway mediates EMT, and specific WNT/FZD interactions have been related to the activation of this process in several diseases. We aim to analyse the relevance of EMT and WNT ligands and receptors in the penetrating behaviour of CD. Methods Intestinal surgical resections were obtained from control and CD patients with a stenotic or penetrating behaviour. Fibrosis was determined by the histological analysis of collagen deposition and EMT by confocal microscopy. The expression of WNT ligands, inh…

Male0301 basic medicineWNT pathwayVimentin0302 clinical medicineCrohn DiseaseFibrosisMedicineIntestinal MucosaReceptorWnt Signaling PathwayAged 80 and overbiologyGastroenterologyWnt signaling pathwayGeneral MedicineMiddle AgedCrohn's disease10219 Clinic for Gastroenterology and Hepatology030220 oncology & carcinogenesisembryonic structuresFemaleHT29 CellsAdultEpithelial-Mesenchymal TransitionAdolescentColonBlotting Western610 Medicine & healthReal-Time Polymerase Chain ReactionYoung Adult03 medical and health sciencesHT29 CellsHumansImmunoprecipitation2715 GastroenterologyEpithelial–mesenchymal transitionCrohn´s disease WNT pathway fibrosisAgedGlycoproteinsCadherinbusiness.industryfibrosismedicine.diseaseFibrosisFrizzled ReceptorsIn vitroWnt Proteins030104 developmental biologyCancer researchbiology.proteinbusiness
researchProduct

Cholesterol burden in the liver induces mitochondrial dynamic changes and resistance to apoptosis

2018

Non-alcoholic fatty liver disease (NAFLD) encompasses a broad spectrum of histopathological changes ranging from non-inflammatory intracellular fat deposition to non-alcoholic steatohepatitis (NASH), which may progress into hepatic fibrosis, cirrhosis, or hepatocellular carcinoma. Recent data suggest that impaired hepatic cholesterol homeostasis and its accumulation are relevant to the pathogenesis of NAFLD/NASH. Despite a vital physiological function of cholesterol, mitochondrial dysfunction is an important consequence of dietary-induced hypercholesterolemia and was, subsequently, linked to many pathophysiological conditions. The aim in the current study was to evaluate the morphological a…

Male0301 basic medicinemedicine.medical_specialtyTime FactorsCirrhosisPhysiologyClinical BiochemistryApoptosisMitochondria LiverMitochondrionDiet High-Fatmedicine.disease_causeMitochondrial DynamicsCholesterol Dietary03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNon-alcoholic Fatty Liver DiseaseInternal medicinemedicineAnimalsCells CulturedCell ProliferationCholesterolbusiness.industryFatty liverCell Biologymedicine.diseaseMice Inbred C57BLDisease Models AnimalOxidative Stress030104 developmental biologymedicine.anatomical_structureEndocrinologyGene Expression RegulationLiverchemistry030220 oncology & carcinogenesisHepatocyteHepatocytesSteatohepatitisTranscriptomeHepatic fibrosisbusinessOxidative stressJournal of Cellular Physiology
researchProduct

Modulation of the gut microbiota impacts nonalcoholic fatty liver disease: A potential role for bile acids

2017

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease worldwide, yet the pathogenesis of NAFLD is only partially understood. Here, we investigated the role of the gut bacteria in NAFLD by stimulating the gut bacteria via feeding mice the fermentable dietary fiber, guar gum (GG), and suppressing the gut bacteria via chronic oral administration of antibiotics. GG feeding profoundly altered the gut microbiota composition, in parallel with reduced diet-induced obesity and improved glucose tolerance. Strikingly, despite reducing adipose tissue mass and inflammation, GG enhanced hepatic inflammation and fibrosis, concurrent with markedly elevated plasma and hepatic bile acid l…

Male0301 basic medicineobesityGut floraGalactansGastroenterologyBiochemistryantibioticsMannansSTEATOHEPATITISVoeding Metabolisme en Genomicachemistry.chemical_compoundLiver diseaseEndocrinologyNon-alcoholic Fatty Liver DiseaseFibrosisAntibioticsPlant GumsNonalcoholic fatty liver diseaseHeptaic inflammationFIBROSIShepatic fibrosisResearch ArticlesHuman Nutrition & HealthbiologyBile acidHumane Voeding & GezondheidMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Metabolism and GenomicsAnti-Bacterial Agents3. Good healthIntestineL-CARNITINELiverGUAR GUM[ SDV.BBM.GTP ] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]Metabolisme en Genomica[SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]Nutrition Metabolism and Genomics[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.medical_specialtymedicine.drug_classBiochemieCelbiologie en ImmunologieQD415-436Gut microbiotaMETABOLISMDiet High-Fatdigestive systemDIET03 medical and health sciencesVoedingINFLAMMATIONINTESTINAL MICROBIOTAInternal medicine[SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry Molecular Biology/Genomics [q-bio.GN]medicineAnimalsHepatic inflammationObesityintestineVLAGNutritionInflammationBile acids and saltshepatic inflammationBiological Transport[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyCell BiologyGlucose Tolerance Testmedicine.diseaseTaurocholic acidbiology.organism_classification[SDV.MHEP.HEG] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyGastrointestinal MicrobiomeMice Inbred C57BLMICE030104 developmental biologyEndocrinologychemistryCell Biology and ImmunologySteatohepatitisHepatic fibrosisTRIMETHYLAMINE-N-OXIDEHepatic fibrosis
researchProduct

Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort.

2021

Background In patients treated for HCV infection, potential drug–drug interactions (DDIs) can occur among direct-acting antiviral drugs (DAAs) and comedications used. The real-life effectiveness and safety of elbasvir/grazoprevir (ELB/GZR) among co-medicated HCV patients was evaluated. Methods We prospectively evaluated consecutive patients from 15 clinical centres participating in PITER who were treated with ELB/GZR and had been followed for at least 12 weeks after treatment. Data were prospectively collected on the use of comedications (including discontinuation, dose modification and addition of drugs) and potential DDIs with DAAs. Results Of the 356 patients with at least 12-week post-t…

Male030312 virologycombination therapytreatment experienced patientsDrug Combinationchronic hepatitis C drug drug interactions virus genotype 1 treatment experienced patients pump inhibitor use combination therapy treatment naive liver fibrosisgrazoprevir elbasvir80 and overAge FactorPharmacology (medical)Drug InteractionsProspective StudiesChronicProspective cohort studyliver fibrosisAged 80 and over0303 health sciencesAge FactorsImidazolesMiddle AgedHepatitis CDrug CombinationsInfectious DiseasesTreatment OutcomeDrug InteractionGrazoprevirCohortdrug drug interactionsFemalepump inhibitor useHumanmedicine.drugmedicine.medical_specialtyElbasvirQuinoxalinetreatment naiveelbasvirAntiviral AgentsNO03 medical and health sciencesInternal medicineQuinoxalinesmedicinechronic hepatitis CElbasvir GrazoprevirHumansImidazoleAgedBenzofuransAntiviral AgentPharmacology...business.industrygrazoprevirCarbamazepineHepatitis C Chronicmedicine.diseaseComorbidityDiscontinuationBenzofuranAge Factors; Aged; Aged 80 and over; Antiviral Agents; Benzofurans; Drug Combinations; Drug Interactions; Female; Hepatitis C Chronic; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Quinoxalines; Treatment Outcomebusinessvirus genotype 1Antiviral therapy
researchProduct

Prevalence and prognostic impact of nonischemic late gadolinium enhancement in stress cardiac magnetic resonance

2020

Aim To assess the prevalence and prognostic significance of NI-LGE in patients undergoing stress-CMR. Methods Stress-CMR with either dipyridamole or adenosine was performed in 283 patients (228 men, 81%) including perfusion imaging, wall motion evaluation and LGE. Follow-up was completed in all enrolled patients (median time: 1850 days; interquartile range: 1225-2705 days). Composite endpoint included cardiac death, ventricular tachycardia, myocardial infarction, stroke, hospitalization for cardiac cause and coronary revascularization performed beyond 90 days from stress-CMR scans. Results One hundred and twelve patients (40%) had negative LGE (no-LGE), 140 patients (49%) I-LGE and 31 patie…

MaleAdenosineTime FactorsVasodilator AgentsContrast MediaPerfusion scanning030204 cardiovascular system & hematologyVentricular tachycardia0302 clinical medicineRisk FactorsInterquartile rangePrevalence030212 general & internal medicineMyocardial infarctionStrokenonischemic fibrosislate gadolinium enhancement; nonischemic cardiac findings; nonischemic fibrosis; prognosis; stress perfusion cardiac magnetic resonanceDipyridamoleGeneral MedicineMiddle AgedMagnetic Resonance ImagingDipyridamolelate gadolinium enhancementstress perfusion cardiac magnetic resonanceembryonic structurescardiovascular systemCardiologyFemaleCardiology and Cardiovascular MedicinePerfusionmedicine.drugnonischemic cardiac findingsmedicine.medical_specialtyHeart DiseasesPerfusion ImagingRisk Assessment03 medical and health sciencesPredictive Value of TestsInternal medicinemedicineHumanscardiovascular diseasesSurvival analysisAgedRetrospective Studiesbusiness.industryMyocardiummedicine.diseaseFibrosisLate gadolinium enhancement Nonischemic cardiac findings Nonischemic fibrosis Prognosis Stress perfusion cardiac magnetic resonanceprognosisbusinessJournal of Cardiovascular Medicine
researchProduct

Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching

2017

Introduction Current treatment with vasodilators for pulmonary hypertension associated with respiratory diseases is limited by their inhibitory effect on hypoxic pulmonary vasoconstriction (HPV) and uncoupling effects on ventilation-perfusion (V'/Q'). Hypoxia is also a well-known modulator of the nitric oxide (NO) pathway, and may therefore differentially affect the responses to phosphodiesterase 5 (PDE5) inhibitors and soluble guanylyl cyclase (sGC) stimulators. So far, the effects of the sGC stimulator riociguat on HPV have been poorly characterized. Materials and methods Contraction was recorded in pulmonary arteries (PA) in a wire myograph. Anesthetized rats were catheterized to record …

MaleAnoxemiaPulmonologyPulmonary FibrosisVasodilator Agentslcsh:MedicineVasodilation030204 cardiovascular system & hematologyPharmacologyVascular Medicinechemistry.chemical_compound0302 clinical medicineSoluble Guanylyl CyclaseHypoxic pulmonary vasoconstrictionPulmonary fibrosisMedicine and Health SciencesPulmonary Arterieslcsh:ScienceHypoxiaMultidisciplinaryVasodilatorsDrugsRespiratory organs diseasesArteriesMiddle AgedChemistryPhysical Sciencescardiovascular systemFemalemedicine.symptomAnatomyMedicamentsmedicine.drugResearch ArticleChemical Elementsinorganic chemicalsSildenafilHypertension PulmonaryChronic Obstructive Pulmonary DiseaseEnzyme ActivatorsIn Vitro TechniquesPulmonary ArteryRiociguatSildenafil CitrateMalalties de l'aparell respiratori03 medical and health sciencesMedical HypoxiamedicineVentilation-Perfusion RatioAnimalsHumansRats WistarAgedPharmacologybusiness.industrylcsh:RAnoxèmiaBiology and Life SciencesHypoxia (medical)Phosphodiesterase 5 Inhibitorsmedicine.diseasePulmonary hypertensionFibrosisRatsOxygenDisease Models AnimalPyrimidines030228 respiratory systemchemistryVasoconstrictionCardiovascular AnatomyPyrazolesBlood Vesselslcsh:QSoluble guanylyl cyclasebusinessDevelopmental Biology
researchProduct

No evidence of adverse cardiac remodeling in former elite endurance athletes

2016

Background: The impact of high exercise loads on a previously healthy heart remains controversial. We examined the consequences of decades of strenuous endurance exercise at the highest competition level on heart dimensions and volumes as well as on serum biomarkers of cardiac fibrosis/remodeling. Methods and results: We compared echocardiographic measurements and serum biomarkers of cardiac fibrosis/remodeling [troponin I, galectin-3, matrix metallopeptidase-2 and -9, N-terminal pro-brain natriuretic peptide, carboxy-terminal propeptide of type I procollagen, and soluble suppressor of tumorigenicity-2 (sST-2)/interleukin(IL)-1R4] in 53 male athletes [11 former professional ('elite') and 42…

MaleCardiac fibrosis030204 cardiovascular system & hematology0302 clinical medicineReference ValuesTroponin INatriuretic peptideVentricular FunctionAtletismo - Aspectos fisiológicosBody surface areaVentricular RemodelingCorazónmedicine.diagnostic_testbiologyOrgan SizeMiddle AgedEndurance exercisePathophysiologyEchocardiographyHeart Function TestsCardiologyCardiology and Cardiovascular MedicineSportsAdultmedicine.medical_specialtymedicine.drug_classHeart VentriclesMagnetic Resonance Imaging CineTime03 medical and health sciencesCardiac magnetic resonance imagingEndurance trainingAtletaInternal medicinemedicineHumansExerciseCardiac remodelingSistema cardiovascularCardiac fibrosisbusiness.industryAthletes030229 sport sciencesmedicine.diseasebiology.organism_classificationEndocrinologyAthletesPhysical FitnessPhysical EndurancebusinessInternational Journal of Cardiology
researchProduct

Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype…

2017

Over the last 5 years, therapies for hepatitis C virus (HCV) infection have improved significantly, achieving sustained virologic response (SVR) rates of up to 100% in clinical trials in patients with HCV genotype 1. We investigated the effectiveness and safety of ombitasvir/paritaprevir/ritonavir +/- dasabuvir in an early access programme. This was a retrospective, multicentre, national study that included 291 treatment-naive and treatment-experienced patients with genotype 1 or 4 HCV infection. Most patients (65.3%) were male, and the mean age was 57.5years. The mean baseline viral load was 6.1 log, 69.8% had HCV 1b genotype, 72.9% had cirrhosis and 34.7% were treatment-naive. SVR at 12 w…

MaleCirrhosisSustained Virologic ResponseHepacivirusmedicine.disease_causechemistry.chemical_compound0302 clinical medicinesevere fibrosisdasabuvirMedicineAged 80 and overMiddle AgedInfectious DiseasesTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleViral loadmedicine.drugAdultmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsGenotypeHepatitis C viruscompassionate useAntiviral Agents03 medical and health sciencesVirologyInternal medicineHumansAdverse effectAgedRetrospective StudiesHepatologybusiness.industryRibavirinparitaprevirHepatitis C Chronicmedicine.diseaseVirologydigestive system diseasesOmbitasvirDiscontinuationombitasvirchemistryParitaprevirSpainhepatitis Cbusiness
researchProduct

Unexplained chronic liver disease in Ethiopia: a cross-sectional study

2018

Background Hepatitis B virus (HBV) infection is assumed to be the major cause of chronic liver disease (CLD) in sub-Saharan Africa. The contribution of other aetiological causes of CLD is less well documented and hence opportunities to modulate other potential risk factors are being lost. The aims of this study were to explore the aetiological spectrum of CLD in eastern Ethiopia and to identify plausible underlying risk factors for its development. Methods A cross-sectional study was undertaken between April 2015 and April 2016 in two public hospitals in Harar, eastern Ethiopia. The study population comprised of consenting adults with clinical and radiological evidence of chronic liver dise…

MaleCross-sectional studyEpidemiologyBiopsyChronic liver disease0302 clinical medicineRisk FactorsKhatEpidemiologyPrevalenceSIMPLE NONINVASIVE INDEX030212 general & internal medicineViral hepatitisPOPULATIONbiologymedicine.diagnostic_testSub-Saharan AfricaLiver DiseasesGastroenterologyCHRONIC HEPATITISGeneral MedicineAlcoholismLiverLiver biopsyPopulation studyFemale030211 gastroenterology & hepatologyC HEPATITISViral hepatitisLife Sciences & BiomedicineResearch ArticleAdultmedicine.medical_specialtySubstance-Related DisordersAcute Lung InjuryKHAT LEAVESAUTOIMMUNEVERBAL AUTOPSY METHODCathaVIRUS-INFECTIONCatha edulis03 medical and health sciencesInternal medicinemedicineHumanslcsh:RC799-869Science & TechnologyGastroenterology & HepatologySIGNIFICANT FIBROSISbusiness.industryHepatotoxicity1103 Clinical SciencesHepatologybiology.organism_classificationmedicine.diseaseCross-Sectional StudiesChronic Diseaselcsh:Diseases of the digestive system. GastroenterologyEthiopiabusiness
researchProduct

[Gadolinium-containing contrast agents: Gadoterat-meglumine is safe in patients with chronic renal failure].

2014

Objective To prospectively compare the renal safety of meglumine gadoterate (Gd-DOTA)-enhanced magnetic resonance imaging (MRI) to a control group (unenhanced MRI) in high-risk patients. Methods Patients with chronic kidney disease (CKD) scheduled for MRI procedures were screened. The primary endpoint was the percentage of patients with an elevation of serum creatinine levels, measured 72 ± 24 h after the MRI procedure, by at least 25 % or 44.2 μmol/l (0.5 mg/dl) from baseline. A non-inferiority margin of the between-group difference was set at −15 % for statistical analysis of the primary endpoint. Main secondary endpoints were the variation in serum creatinine and eGFR values between base…

MaleDrug-Related Side Effects and Adverse ReactionsContrast MediaAcute Kidney InjuryMeglumine gadoterateMagnetic Resonance ImagingNephrogenic Fibrosing DermopathyHeterocyclic CompoundsGd-DOTANephrogenic systemic fibrosisOrganometallic CompoundsHumansFemaleRenal Insufficiency ChronicGadolinium-based contrast agent-induced nephropathyMRIRoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin
researchProduct